Cue Health (HLTH) Stock Forecast, Price Target & Predictions
HLTH Stock Forecast
Cue Health stock forecast is as follows: an average price target of $8.00 (represents a 114185.71% upside from HLTH’s last price of $0.01) and a rating consensus of 'Hold', based on 1 wall street analysts offering a 1-year stock forecast.
HLTH Price Target
The average price target for Cue Health (HLTH) is $8.00 based on 1-year price targets from 1 Wall Street analysts in the past 3 months, with a price target range of $8.00 to $8.00. This represents a potential 114185.71% upside from HLTH's last price of $0.01.
HLTH Analyst Ratings
According to 1 Wall Street analysts, Cue Health's rating consensus is 'Hold'. The analyst rating breakdown for HLTH stock is 0 'Strong Buy' (0.00%), 0 'Buy' (0.00%), 1 'Hold' (100.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Cue Health Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Aug 11, 2022 | - | Morgan Stanley | $8.00 | $4.96 | 61.29% | 114185.71% |
| May 12, 2022 | - | Morgan Stanley | $10.00 | $5.25 | 90.47% | 142757.14% |
The latest Cue Health stock forecast, released on Aug 11, 2022 by Morgan Stanley company, set a price target of $8.00, which represents a 61.29% increase from the stock price at the time of the forecast ($4.96), and a 114185.71% increase from HLTH last price ($0.01).
Cue Health Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | - |
| Avg Price Target | - | - | - |
| Last Closing Price | $0.01 | $0.01 | $0.01 |
| Upside/Downside | -100.00% | -100.00% | -100.00% |
In the current month, the average price target of Cue Health stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Cue Health's last price of $0.01. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 11, 2022 | Morgan Stanley | Equal-Weight | Equal-Weight | Hold |
| May 12, 2022 | Morgan Stanley | Equal-Weight | Equal-Weight | Hold |
Cue Health's last stock rating was published by Morgan Stanley on Aug 11, 2022. The company gave HLTH a "Equal-Weight" rating, the same as its previous rate.
Cue Health Financial Forecast
Cue Health Revenue Forecast
| Dec 25 | Oct 25 | Jul 25 | Mar 25 | Dec 24 | Oct 24 | Jul 24 | Mar 24 | Dec 23 | Oct 23 | Jul 23 | Mar 23 | Dec 22 | Oct 22 | Jul 22 | Mar 22 | Dec 21 | Oct 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | $18.80M | - | - | $24.49M | $146.78M | - | - | $177.45M | $192.51M | - |
| Avg Forecast | $31.80M | $23.40M | $19.00M | $25.80M | $26.32M | $15.73M | $9.40M | $10.10M | $17.68M | $11.81M | $8.92M | $23.02M | $47.78M | $58.17M | $52.91M | $175.15M | $190.66M | $200.32M |
| High Forecast | $31.80M | $23.40M | $19.00M | $25.80M | $26.32M | $15.73M | $9.40M | $10.10M | $17.68M | $11.81M | $8.92M | $23.02M | $47.78M | $58.17M | $52.91M | $175.15M | $190.66M | $200.32M |
| Low Forecast | $31.80M | $23.40M | $19.00M | $25.80M | $26.32M | $15.73M | $9.40M | $10.10M | $17.68M | $11.81M | $8.92M | $23.02M | $47.78M | $58.17M | $52.91M | $175.15M | $190.66M | $200.32M |
| # Analysts | - | - | - | - | - | - | - | 1 | 2 | 1 | 1 | 1 | - | - | - | - | 1 | 1 |
| Surprise % | - | - | - | - | - | - | - | - | 1.06% | - | - | 1.06% | 3.07% | - | - | 1.01% | 1.01% | - |
Cue Health's average Quarter revenue forecast for Mar 24 based on 1 analysts is $10.10M, with a low forecast of $10.10M, and a high forecast of $10.10M. HLTH's average Quarter revenue forecast represents a -46.25% decrease compared to the company's last Quarter revenue of $18.80M (Dec 23).
Cue Health EBITDA Forecast
| Dec 25 | Oct 25 | Jul 25 | Mar 25 | Dec 24 | Oct 24 | Jul 24 | Mar 24 | Dec 23 | Oct 23 | Jul 23 | Mar 23 | Dec 22 | Oct 22 | Jul 22 | Mar 22 | Dec 21 | Oct 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | 1 | 2 | 1 | 1 | 1 | - | - | - | - | 1 | 1 |
| EBITDA | - | - | - | - | - | - | - | - | $-50.06M | - | - | $-86.11M | $-36.59M | - | - | $13.46M | $30.10M | - |
| Avg Forecast | $-20.38M | $-15.00M | $-12.18M | $-16.53M | $-16.86M | $-10.08M | $-6.02M | $-6.47M | $-11.33M | $-7.57M | $-5.72M | $-14.75M | $-30.62M | $-37.28M | $-33.91M | $29.07M | $-122.18M | $77.13M |
| High Forecast | $-20.38M | $-15.00M | $-12.18M | $-16.53M | $-16.86M | $-10.08M | $-6.02M | $-6.47M | $-11.33M | $-7.57M | $-5.72M | $-14.75M | $-30.62M | $-37.28M | $-33.91M | $34.89M | $-122.18M | $92.55M |
| Low Forecast | $-20.38M | $-15.00M | $-12.18M | $-16.53M | $-16.86M | $-10.08M | $-6.02M | $-6.47M | $-11.33M | $-7.57M | $-5.72M | $-14.75M | $-30.62M | $-37.28M | $-33.91M | $23.26M | $-122.18M | $61.70M |
| Surprise % | - | - | - | - | - | - | - | - | 4.42% | - | - | 5.84% | 1.20% | - | - | 0.46% | -0.25% | - |
0 analysts predict HLTH's average Quarter EBITDA for Jul 22 to be $-33.91M, with a high of $-33.91M and a low of $-33.91M. This is -351.92% lower than Cue Health's previous annual EBITDA (Mar 22) of $13.46M.
Cue Health Net Income Forecast
| Dec 25 | Oct 25 | Jul 25 | Mar 25 | Dec 24 | Oct 24 | Jul 24 | Mar 24 | Dec 23 | Oct 23 | Jul 23 | Mar 23 | Dec 22 | Oct 22 | Jul 22 | Mar 22 | Dec 21 | Oct 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | 1 | 2 | 1 | 1 | 1 | - | - | - | - | 1 | 1 |
| Net Income | - | - | - | - | - | - | - | - | $-148.43M | - | - | $-92.77M | $-31.51M | - | - | $2.80M | $34.23M | - |
| Avg Forecast | $-39.66M | $-41.25M | $-44.42M | $-47.59M | $-26.97M | $-28.55M | $-30.14M | $-59.75M | $-67.82M | $-70.33M | $-81.43M | $-96.37M | $-85.75M | $22.21M | $-73.37M | $6.05M | $17.10M | $23.76M |
| High Forecast | $-39.66M | $-41.25M | $-44.42M | $-47.59M | $-26.97M | $-28.55M | $-30.14M | $-59.75M | $-61.79M | $-70.33M | $-81.43M | $-96.37M | $-85.75M | $26.66M | $-73.37M | $7.27M | $17.10M | $28.51M |
| Low Forecast | $-39.66M | $-41.25M | $-44.42M | $-47.59M | $-26.97M | $-28.55M | $-30.14M | $-59.75M | $-72.34M | $-70.33M | $-81.43M | $-96.37M | $-85.75M | $17.77M | $-73.37M | $4.84M | $17.10M | $19.01M |
| Surprise % | - | - | - | - | - | - | - | - | 2.19% | - | - | 0.96% | 0.37% | - | - | 0.46% | 2.00% | - |
Cue Health's average Quarter net income forecast for Jul 22 is $-73.37M, with a range of $-73.37M to $-73.37M. HLTH's average Quarter net income forecast represents a -2717.50% decrease compared to the company's last Quarter net income of $2.80M (Mar 22).
Cue Health SG&A Forecast
| Dec 25 | Oct 25 | Jul 25 | Mar 25 | Dec 24 | Oct 24 | Jul 24 | Mar 24 | Dec 23 | Oct 23 | Jul 23 | Mar 23 | Dec 22 | Oct 22 | Jul 22 | Mar 22 | Dec 21 | Oct 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | 1 | 2 | 1 | 1 | 1 | - | - | - | - | 1 | 1 |
| SG&A | - | - | - | - | - | - | - | - | $16.09M | - | - | $28.19M | $38.47M | - | - | $61.08M | $44.65M | - |
| Avg Forecast | $24.20M | $17.81M | $14.46M | $19.63M | $20.03M | $11.97M | $7.15M | $7.69M | $13.46M | $8.99M | $6.79M | $17.52M | $36.36M | $44.38M | $40.27M | $131.93M | $145.10M | $47.47M |
| High Forecast | $24.20M | $17.81M | $14.46M | $19.63M | $20.03M | $11.97M | $7.15M | $7.69M | $13.46M | $8.99M | $6.79M | $17.52M | $36.36M | $53.26M | $40.27M | $158.31M | $145.10M | $56.96M |
| Low Forecast | $24.20M | $17.81M | $14.46M | $19.63M | $20.03M | $11.97M | $7.15M | $7.69M | $13.46M | $8.99M | $6.79M | $17.52M | $36.36M | $35.51M | $40.27M | $105.54M | $145.10M | $37.97M |
| Surprise % | - | - | - | - | - | - | - | - | 1.20% | - | - | 1.61% | 1.06% | - | - | 0.46% | 0.31% | - |
Cue Health's average Quarter SG&A projection for Mar 24 is $7.69M, based on 1 Wall Street analysts, with a range of $7.69M to $7.69M. The forecast indicates a -52.22% fall compared to HLTH last annual SG&A of $16.09M (Dec 23).
Cue Health EPS Forecast
| Dec 25 | Oct 25 | Jul 25 | Mar 25 | Dec 24 | Oct 24 | Jul 24 | Mar 24 | Dec 23 | Oct 23 | Jul 23 | Mar 23 | Dec 22 | Oct 22 | Jul 22 | Mar 22 | Dec 21 | Oct 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | 1 | 2 | 1 | 1 | 1 | - | - | - | - | 1 | 1 |
| EPS | - | - | - | - | - | - | - | - | $-0.96 | - | - | $-0.61 | $-0.21 | - | - | $0.02 | $0.23 | - |
| Avg Forecast | $-0.25 | $-0.26 | $-0.28 | $-0.30 | $-0.17 | $-0.18 | $-0.19 | $-0.38 | $-0.43 | $-0.44 | $-0.51 | $-0.61 | $-0.54 | $-0.54 | $-0.46 | $-0.05 | $0.11 | $1.40 |
| High Forecast | $-0.25 | $-0.26 | $-0.28 | $-0.30 | $-0.17 | $-0.18 | $-0.19 | $-0.38 | $-0.39 | $-0.44 | $-0.51 | $-0.61 | $-0.54 | $-0.54 | $-0.46 | $-0.05 | $0.11 | $1.40 |
| Low Forecast | $-0.25 | $-0.26 | $-0.28 | $-0.30 | $-0.17 | $-0.18 | $-0.19 | $-0.38 | $-0.46 | $-0.44 | $-0.51 | $-0.61 | $-0.54 | $-0.54 | $-0.46 | $-0.05 | $0.11 | $1.40 |
| Surprise % | - | - | - | - | - | - | - | - | 2.25% | - | - | 1.00% | 0.39% | - | - | -0.38% | 2.13% | - |
According to 0 Wall Street analysts, Cue Health's projected average Quarter EPS for Jul 22 is $-0.46, with a low estimate of $-0.46 and a high estimate of $-0.46. This represents a -2412.50% decrease compared to HLTH previous annual EPS of $0.02 (Mar 22).
Cue Health Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| HLTH | Cue Health | $0.04 | $8.00 | 19900.00% | Hold |
| AKLI | Akili | $0.43 | $3.25 | 655.81% | Buy |
| HCTI | Healthcare Triangle | $0.45 | $2.00 | 344.44% | Buy |
| HCAT | Health Catalyst | $8.70 | $29.25 | 236.21% | Buy |
| FORA | Forian | $2.22 | $4.50 | 102.70% | Buy |
| CERT | Certara | $10.83 | $21.75 | 100.83% | Hold |
| PINC | Premier | $20.53 | $33.25 | 61.96% | Hold |
| HQY | HealthEquity | $78.80 | $97.00 | 23.10% | Buy |
| CMAX | CareMax | $2.19 | $2.60 | 18.72% | Hold |
| AUGX | Augmedix | $2.33 | $2.67 | 14.59% | Hold |
HLTH Forecast FAQ
Is Cue Health a good buy?
No, according to 1 Wall Street analysts, Cue Health (HLTH) is considered a 'Hold'. The rating consensus is based on 0 'Strong Buy' and 0 'Buy' recommendations, accounting for 0% of HLTH's total ratings.
What is HLTH's price target?
Cue Health (HLTH) average price target is $8 with a range of $8 to $8, implying a 114185.71% from its last price of $0.007. The data is based on 1 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Cue Health stock go up soon?
According to Wall Street analysts' prediction for HLTH stock, the company can go up by 114185.71% (from the last price of $0.007 to the average price target of $8), up by 114185.71% based on the highest stock price target, and up by 114185.71% based on the lowest stock price target.
Can Cue Health stock reach $0?
HLTH's average twelve months analyst stock price target of $8 supports the claim that Cue Health can reach $0 in the near future.
What are Cue Health's analysts' financial forecasts?
Cue Health's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $61.55M (high $61.55M, low $61.55M), average EBITDA is $-39.444M (high $-39.444M, low $-39.444M), average net income is $-145M (high $-145M, low $-145M), average SG&A $46.84M (high $46.84M, low $46.84M), and average EPS is $-0.917 (high $-0.917, low $-0.917). HLTH's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $100M (high $100M, low $100M), average EBITDA is $-64.084M (high $-64.084M, low $-64.084M), average net income is $-173M (high $-173M, low $-173M), average SG&A $76.1M (high $76.1M, low $76.1M), and average EPS is $-1.09 (high $-1.09, low $-1.09).
Did the HLTH's actual financial results beat the analysts' financial forecasts?
Based on Cue Health's last annual report (Dec 2023), the company's revenue was $70.94M, beating the average analysts forecast of $61.44M by 15.46%. Apple's EBITDA was $-395M, beating the average prediction of $-39.371M by 902.91%. The company's net income was $-373M, beating the average estimation of $-316M by 18.20%. Apple's SG&A was $89.94M, beating the average forecast of $46.75M by 92.36%. Lastly, the company's EPS was $-2.44, beating the average prediction of $-1.992 by 22.51%. In terms of the last quarterly report (Dec 2023), Cue Health's revenue was $18.8M, beating the average analysts' forecast of $17.68M by 6.32%. The company's EBITDA was $-50.065M, beating the average prediction of $-11.33M by 341.86%. Cue Health's net income was $-148M, beating the average estimation of $-67.816M by 118.87%. The company's SG&A was $16.09M, beating the average forecast of $13.46M by 19.59%. Lastly, the company's EPS was $-0.96, beating the average prediction of $-0.427 by 124.56%